Drug intelligence / Profile preview

AL-794

Development stage: Phase 1
Lead developer: Janssen Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

AL-794 is an orally active isobutyrate prodrug of ALS-033719, which selectively binds to the endonuclease domain of influenza virus polymerase acidic protein and potently inhibits the endonuclease activity. It has an inhibitory effect on 29 influenza virus A and B strains, with 90% effective concentrations (EC90) ranging from 2.3 to 267 nM. In clinical trials, AL-794 demonstrated significant dose-dependent antiviral activity, with greater decreases in viral load, symptoms, and mucus weight at the 150-mg dose compared to the 50-mg dose.

Targets

CEN (Influenza A virus (2009 H1N1) polymerase acidic protein (PA) endonuclease)

Beyond the preview

Go deeper on AL-794.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AL-794.

Explore the full profile